IGM Biosciences Files 2024 Annual Report Amendment
| Field | Detail |
|---|---|
| Company | Igm Biosciences, Inc. |
| Form Type | 10-K/A |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, biotech
TL;DR
IGM Biosciences filed an amendment to its 2024 10-K, check for updates on financials and strategy.
AI Summary
IGM Biosciences, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 30, 2025, provides updated information regarding the company's financial performance and operations. IGM Biosciences, Inc. is a biopharmaceutical company incorporated in Delaware, focused on developing antibody-based therapies.
Why It Matters
This amendment to the annual report provides updated and potentially revised information for investors and analysts to consider when evaluating IGM Biosciences' financial health and strategic direction.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, IGM Biosciences faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 001-39045 — SEC File Number (Identifies the company's filings with the SEC.)
- 77-0349194 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- IGM Biosciences, Inc. (company) — Registrant
- 20241231 (date) — Fiscal year end
- 20250430 (date) — Filing date
- 325 E. Middlefield Road, Mountain View, CA (address) — Company business address
- Delaware (location) — State of incorporation
FAQ
What specific information was updated or revised in this 10-K/A filing compared to the original 10-K?
The filing is an amendment (10-K/A) to the annual report for the fiscal year ended December 31, 2024, indicating that updates or corrections to the original filing were made.
What is the primary business of IGM Biosciences, Inc.?
IGM Biosciences, Inc. is a biopharmaceutical company focused on developing antibody-based therapies, as indicated by its SIC code 2834 (Pharmaceutical Preparations).
When was the original 10-K filed, and what is the purpose of this amendment?
The original 10-K was for the fiscal year ended December 31, 2024, and this amendment (10-K/A) was filed as of April 30, 2025, to provide updated or corrected information.
Where is IGM Biosciences, Inc. headquartered?
The company's business and mail address is 325 E. Middlefield Road, Mountain View, CA.
What is the company's state of incorporation?
IGM Biosciences, Inc. is incorporated in Delaware.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding IGM Biosciences, Inc..